Patents Assigned to AstraZeneca
  • Chemical compounds
    Patent number: 7547722
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: June 16, 2009
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Zbigniew Stanley Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
  • QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20090149484
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: April 17, 2007
    Publication date: June 11, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • Thioxanthine Derivatives and Their Use as Inhibitors of MPO
    Publication number: 20090149475
    Abstract: There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.
    Type: Application
    Filed: April 12, 2007
    Publication date: June 11, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Anna-Karin Tiden, Jenny Viklund
  • Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases
    Publication number: 20090149448
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Application
    Filed: November 22, 2005
    Publication date: June 11, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Lilian Alcaraz, Roger Victor Bonnert, Anthony Ronald Cook, Timothy Jon Luker, Rukhsana Tasneem Mohammed, Stephen Thom
  • Metabotropic Glutamate Receptor-Potentiating Isoindolones
    Publication number: 20090149505
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, processes for the preparing such compounds, new intermediates employed in their preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 6, 2007
    Publication date: June 11, 2009
    Applicant: AstraZeneca AB
    Inventors: James R. Empfield, James J. Folmer, James R. Arnold, Joshua Clayton, Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma
  • Methods for Assessing the Predisposition or Susceptibility to COPD
    Publication number: 20090149428
    Abstract: This invention relates to novel associations between polymorphisms in the genes encoding the human Epithelial Na+ Channel (ENaC) and COPD. More particularly, the invention relates to a method for assessing the predisposition and/or susceptibility of an individual to COPD, which method comprises detecting the presence of a polymorphism in one or more human ENaC-encoding genes, in particular position 3870 of SEQ ID:1 encoding SCNN1B or position 10544 of SEQ ID NO: 2 encoding SCNN1G. The invention also relates to a method of treating a human identified as having a polymorphism in one or more human ENaC-encoding genes with a drug capable of treating COPD.
    Type: Application
    Filed: November 16, 2005
    Publication date: June 11, 2009
    Applicant: AstraZeneca AB
    Inventor: Simon Smith
  • Spirofuropyridine aryl derivatives
    Patent number: 7544693
    Abstract: Compounds of formula I: wherein Ar is a moiety of formula II or III: and pharmaceutically-acceptable salts thereof, wherein A, B, and R1 are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: June 9, 2009
    Assignee: AstraZeneca AB
    Inventor: Eifion Phillips
  • 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer
    Publication number: 20090143384
    Abstract: The invention concerns pyrimidine derivatives of Formula (I) wherein each of Qa, G1, G2, q, R3, r, R4, X1 and Qb have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
    Type: Application
    Filed: July 7, 2005
    Publication date: June 4, 2009
    Applicant: ASTRAZENECA UK LIMITED
    Inventor: Martin Pass
  • Bi-Aryl or Aryl-Heteroaryl Substituted Indoles
    Publication number: 20090143449
    Abstract: The present invention relates to substituted indoles of Formula (I) useful as pharmaceutical compounds for treating respiratory disorders.
    Type: Application
    Filed: May 25, 2007
    Publication date: June 4, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Roger Victor Bonnert, Timothy Jon Luker, John Cumming
  • Human and rat PGC-3, PPAR-gamma coactivations and splice variants thereof
    Publication number: 20090142351
    Abstract: A novel gene PGC-3, and its role in regulating the transcriptional activity of PPAR? in adipose tissue. PGC-3 is highly expressed in human white adipose tissue and has utility in the development of new therapeutic agents for use in the treatment of obesity and other related disorders such as non-insulin dependent diabetes mellitus, insulin resistance syndrome, dyslipidemia, and atherosclerosis.
    Type: Application
    Filed: October 29, 2007
    Publication date: June 4, 2009
    Applicant: AstraZeneca AB
    Inventors: Kevin Anthony Hart, Carl Thomas Montague, Antonio Vidal-Puig
  • Use of an epitope of vascular endothelial growth factor receptor KDR/Flk-1
    Patent number: 7541027
    Abstract: The present invention relates to the use of the epitope which comprises the tyrosine at position 1214 in the amino acid sequence of the vascular endothelial growth factor receptor, KDR/Flk-1, as a marker in the measurement of a change in the activation state of the KDR/Flk-1 receptor and to probes, such as antibodies, which recognize said epitope. The invention also relates to the use of KDR/Flk-1 epitope Y1214 as a marker in the detection of and/or measurement of the level of the KDR/Flk-1 receptor and to assays which utilize the use of the Y1214 epitope and to compounds derived from said assays.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: June 2, 2009
    Assignee: Astrazeneca AB
    Inventor: Sue Ann Cartlidge
  • L-Phenylalanine Derivatives
    Publication number: 20090137601
    Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
    Type: Application
    Filed: November 22, 2006
    Publication date: May 28, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Simon Thomas Barry, Jason Grant Kettle, David Alan Rudge
  • Chemical Compounds
    Publication number: 20090137624
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: February 15, 2006
    Publication date: May 28, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Michelle Lamb, Tao Wang, Dingwel Yu, Yongxin Han, Peter Mohr, Bin Wang
  • Method and system for dosing a pharmaceutical sample in a packaging machine
    Patent number: 7536843
    Abstract: The present invention relates to a method and system for dosing a pharmaceutical product in a packaging machine having at least one volumetric dosing unit with a dosing chamber. The system check-weighs the volumetrically dosed product with appropriate speed and is integrated into a filling or packaging machine. In accordance with the invention, a volume of a first pharmaceutical component is metered and weighed before being introduced into a package. The procedure is repeated with a second pharmaceutical component. The package containing the components is then weighed. Advantageously, accuracy and precision of the amount of the weighed components can be monitored with the present invention to secure the quality of the pharmaceutical product.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: May 26, 2009
    Assignee: AstraZeneca AB
    Inventors: Alf Djurle, Reiner Wurst
  • 2-Thioxanthine Derivatives Acting as MPO-Inhibitors
    Publication number: 20090131459
    Abstract: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, to compositions containing the compound and the use thereof in therapy.
    Type: Application
    Filed: June 4, 2007
    Publication date: May 21, 2009
    Applicant: ASTRAZENECA AB
    Inventor: Anna-Karin Tiden
  • NOVEL COMPOUNDS
    Publication number: 20090131463
    Abstract: The invention provides compounds of formula in which R1, R2, R3 and R4 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Application
    Filed: January 26, 2009
    Publication date: May 21, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Andrew Pape, Andrew Thomas
  • Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity
    Publication number: 20090131444
    Abstract: The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans.
    Type: Application
    Filed: May 23, 2006
    Publication date: May 21, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Folkert Reck, Marshall Morningstar, Hajnalka Hartl
  • New compounds 067
    Publication number: 20090131454
    Abstract: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.
    Type: Application
    Filed: October 17, 2008
    Publication date: May 21, 2009
    Applicant: AstraZeneca AB
    Inventors: Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tao Xin
  • Bis-(Sulfonylamino) Derivatives in Therapy 065
    Publication number: 20090131468
    Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: November 14, 2008
    Publication date: May 21, 2009
    Applicant: AstraZeneca AB
    Inventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
  • Disposable inhaler
    Patent number: 7533668
    Abstract: A disposable inhaler for administering medicament by inhalation having an inhalation channel through which a user may inhale, a container for containing a dose of medicament, at least one subsidiary container for containing a subsidiary dose of medicament and respective release means for selectively opening one or both of said container and said subsidiary container such that one or both of said dose and said subsidiary dose may be released into said inhalation channel at the same time so as to provide a variable dose and methods of providing a variable quantity of substance in a channel comprising opening a first container containing the substance and selectively opening a second container containing the substance.
    Type: Grant
    Filed: April 10, 1998
    Date of Patent: May 19, 2009
    Assignee: AstraZeneca AB
    Inventor: Carin Widerström